News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
590,007 Results
Type
Article (39038)
Company Profile (217)
Press Release (550746)
Multimedia
Podcasts (135)
Webinars (18)
Section
Business (164806)
Career Advice (1219)
Deals (29055)
Drug Delivery (112)
Drug Development (61913)
Employer Resources (112)
FDA (14418)
Job Trends (11882)
News (273847)
Policy (23889)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Elite (2)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (4)
2027 Genetown Standard (4)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2285)
Academic (1)
Accelerated approval (49)
ADA (39)
Adcomms (17)
Allergies (150)
Alliances (45263)
ALS (179)
Alzheimer's disease (1463)
Antibody-drug conjugate (ADC) (472)
Approvals (14878)
Artificial intelligence (759)
ASCO (273)
Autoimmune disease (297)
Automation (68)
Bankruptcy (220)
Best Places to Work (9710)
BIO (56)
BIOSECURE Act (13)
Biosimilars (186)
Biotechnology (161)
Bladder cancer (180)
Brain cancer (69)
Breast cancer (638)
Cancer (5440)
Cardiovascular disease (418)
Career advice (1053)
Career pathing (26)
CAR-T (343)
CDC (31)
Celiac Disease (2)
Cell therapy (932)
Cervical cancer (48)
Clinical research (54035)
Collaboration (2179)
Commercialization (1)
Company closure (3)
Compensation (741)
Complete response letters (66)
COVID-19 (2298)
CRISPR (128)
C-suite (1117)
Cystic fibrosis (157)
Data (7524)
Decentralized trials (2)
Denatured (43)
Depression (153)
Dermatology (80)
Diabetes (534)
Diagnostics (6736)
Digital health (61)
Diversity (9)
Diversity, equity & inclusion (32)
Drug discovery (360)
Drug pricing (115)
Drug shortages (17)
Duchenne muscular dystrophy (316)
Earnings (69051)
Editorial (53)
Employer branding (17)
Employer resources (102)
Events (86162)
Executive appointments (982)
FDA (18025)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (22)
Frontotemporal dementia (29)
Funding (1687)
Gene editing (276)
Generative AI (73)
Gene therapy (854)
GLP-1 (782)
Government (3054)
Grass and pollen (5)
Guidances (394)
Healthcare (15542)
Hematology (157)
HIV (73)
Huntington's disease (63)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (96)
Immunology and inflammation (218)
Immuno-oncology (99)
Indications (181)
Infectious disease (2614)
Inflammatory bowel disease (191)
Inflation Reduction Act (11)
Influenza (133)
Intellectual property (289)
Interviews (196)
IPO (13349)
IRA (22)
Job creations (2548)
Job search strategy (887)
JPM (54)
Kidney cancer (18)
Labor market (61)
Layoffs (428)
Leadership (26)
Legal (5650)
Liver cancer (92)
Longevity (29)
Lung cancer (720)
Lymphoma (420)
Machine learning (64)
Management (31)
Manufacturing (1057)
Marketing (2)
MASH (148)
Medical affairs (1)
Medical device (13227)
Medtech (13402)
Mergers & acquisitions (16881)
Metabolic disorders (1256)
mRNA (238)
Multiple sclerosis (159)
NASH (13)
Neurodegenerative disease (399)
Neuropsychiatric disorders (85)
Neuroscience (2874)
Neurotech (1)
NextGen: Class of 2026 (5090)
Non-profit (3192)
Now hiring (41)
Obesity (550)
Opinion (267)
Ovarian cancer (199)
Pain (235)
Pancreatic cancer (293)
Parkinson's disease (338)
Partnered (32)
Patents (577)
Patient recruitment (664)
Peanut (48)
People (49207)
Pharmaceutical (30)
Pharmacy benefit managers (25)
Phase 1 (17955)
Phase 2 (23829)
Phase 3 (17496)
Pipeline (8994)
Policy (210)
Postmarket research (1577)
Preclinical (7737)
Press Release (72)
Prostate cancer (298)
Psychedelics (40)
Radiopharmaceuticals (340)
Rare diseases (1153)
Real estate (4684)
Recruiting (48)
Regulatory (20090)
Reports (32)
Research institute (2203)
Resumes & cover letters (202)
Rett syndrome (44)
RNA editing (28)
RSV (73)
Schizophrenia (157)
Series A (304)
Series B (214)
Service/supplier (9)
Sickle cell disease (126)
Special edition (16)
Spinal muscular atrophy (179)
Sponsored (45)
Startups (3303)
State (2)
Stomach cancer (13)
Supply chain (100)
Tariffs (50)
The Weekly (89)
Vaccines (989)
Venture capital (102)
Weight loss (317)
Women's health (111)
Worklife (10)
Date
Today (108)
Last 7 days (447)
Last 30 days (2161)
Last 365 days (26023)
2026 (13879)
2025 (25730)
2024 (29986)
2023 (34160)
2022 (44820)
2021 (48073)
2020 (45429)
2019 (37938)
2018 (28756)
2017 (27853)
2016 (26435)
2015 (30895)
2014 (23204)
2013 (25341)
2012 (20642)
2011 (21065)
2010 (19181)
Location
Africa (630)
Alabama (84)
Alaska (6)
Arizona (278)
Arkansas (14)
Asia (41278)
Australia (6711)
California (11476)
Canada (3394)
China (1364)
Colorado (537)
Connecticut (500)
Delaware (345)
Europe (83679)
Florida (1828)
Georgia (372)
Hawaii (3)
Idaho (50)
Illinois (934)
India (97)
Indiana (569)
Iowa (23)
Japan (576)
Kansas (122)
Kentucky (46)
Louisiana (48)
Maine (58)
Maryland (1395)
Massachusetts (8451)
Michigan (363)
Minnesota (619)
Mississippi (7)
Missouri (150)
Montana (31)
Nebraska (23)
Nevada (118)
New Hampshire (89)
New Jersey (3167)
New Mexico (27)
New York (3001)
North Carolina (1381)
North Dakota (11)
Northern California (5793)
Ohio (370)
Oklahoma (19)
Oregon (32)
Pennsylvania (2216)
Puerto Rico (30)
Rhode Island (47)
South America (870)
South Carolina (86)
South Dakota (2)
Southern California (4548)
Tennessee (179)
Texas (1913)
United States (41174)
Utah (367)
Vermont (2)
Virginia (283)
Washington D.C. (48)
Washington State (947)
West Virginia (4)
Wisconsin (131)
Wyoming (2)
590,007 Results for "oxford gene technology ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Lilly adds gene delivery technology to CAR T in up to $7B Kelonia deal
After entering the CAR T space in February, Eli Lilly is “jumping into in vivo CAR-T with both feet” with the acquisition of Kelonia Therapeutics and its gene delivery technology.
April 20, 2026
·
2 min read
·
Annalee Armstrong
Neuroscience
UniQure’s chronic epilepsy gene therapy ‘should be on investors’ radar’
As uniQure prepares its closely watched Huntington’s disease gene therapy for FDA review, the biotech is also making waves in chronic epilepsy with another gene therapy that Stifel says is off to a “promising start.”
June 22, 2026
·
3 min read
·
Tristan Manalac
Press Releases
Andelyn Biosciences and ENCell Co., Ltd Announce Strategic Partnership to Expand Global Reach of Gene Therapy Manufacturing
April 21, 2026
·
4 min read
Duchenne muscular dystrophy
REGENXBIO bets on FDA flexibility with filing plans for Duchenne gene therapy
A few short days after announcing an FDA pivot on a separate asset, REGENXBIO is planning to test the agency’s apparent newfound rare disease outlook on another late-stage gene therapy.
June 24, 2026
·
2 min read
·
Gabrielle Masson
Editorial
BIO 2026: Cell and gene therapy sector must break the mold to thrive
If cell and gene therapy makers are going to achieve their mission to improve patients’ lives, the industry must come together to share information across stakeholders, from regulators to manufacturers to payers.
June 22, 2026
·
4 min read
·
Jef Akst
Rare diseases
Intellia’s gene editor ‘keeps pace’ with Ionis in hereditary angioedema
With a one-time dosing profile, Intellia Therapeutics’ gene editing asset could be “paradigm-shifting” for hereditary angioedema, according to Jefferies. The biotech anticipates market approval next year.
June 16, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China
The combined business entity with Boundless Bio, which will carry Serapha Bio’s name and fold in Boundless Bio, will focus on the development of a gene editor for alpha-1 antitrypsin deficiency.
June 24, 2026
·
2 min read
·
Tristan Manalac
Opinion
The next FDA commissioner must be a champion for gene therapies
The FDA must provide consistent and predictable regulatory frameworks if the U.S. is to maintain its leadership in gene therapy, one of the most consequential therapeutic fields of our generation.
June 5, 2026
·
4 min read
·
Erik Paulsen
FDA
REGENXBIO to resubmit application for Hunter gene therapy after FDA’s most recent pivot
The resubmission for RGX-121, expected in the third quarter, comes as the FDA has deemed REGENXBIO’s existing data “sufficient” to support an accelerated filing. It immediately follows a similar reversal of position regarding uniQure’s embattled Huntington’s disease gene therapy.
June 22, 2026
·
3 min read
·
Heather McKenzie
Gene therapy
4 spaces primed for the next wave of gene therapies
The recent approval of Regeneron’s Otarmeni underscores the maturation of gene therapies across a range of diseases. Here,
BioSpace
reviews genetic medicines in development for the central nervous system, retinal, cardiac and neuromuscular diseases.
May 18, 2026
·
8 min read
·
Andrea Park
1 of 59,001
Next
